PHARMACODYNAMICS EXAM QUESTIONS
AND CORRECT ANSWERS (VERIFIED
ANSWERS) PLUS RATIONALES 2026
Section 1: Basic Principles of Pharmacodynamics
(Questions 1–25)
1. Which of the following best defines pharmacodynamics?
• A) The study of drug absorption, distribution, metabolism, and excretion
• B) The study of the biochemical and physiological effects of drugs and their
mechanisms of action
• C) The study of drug formulation and stability
• D) The study of adverse drug reactions
Answer: B
Rationale: Pharmacodynamics describes "what the drug does to the body" — the
interaction with receptors, signaling pathways, and resulting effects.
Pharmacokinetics (A) is "what the body does to the drug."
2. A drug that binds to a receptor and produces a maximal biological response is
called a:
• A) Partial agonist
• B) Antagonist
, • C) Full agonist
• D) Inverse agonist
Answer: C
*Rationale: A full agonist has high intrinsic activity (efficacy = 1) and produces a
maximal response (100% Emax) at sufficient concentration. A partial agonist (A)
produces a submaximal response even at full receptor occupancy.*
3. A drug that binds to the same receptor as an agonist but produces no response
and prevents the agonist from binding is a:
• A) Competitive antagonist
• B) Partial agonist
• C) Inverse agonist
• D) Allosteric modulator
Answer: A
Rationale: A competitive antagonist binds reversibly to the same site as the
agonist, blocking agonist binding without activating the receptor. It shifts the
dose-response curve to the right without changing Emax.
4. Which of the following statements about the dose-response curve is correct?
• A) The maximal effect (Emax) is determined by potency
• B) Potency is the dose required to produce 50% of maximal effect (EC50)
• C) Efficacy is the dose required to produce a response
• D) A more potent drug always has higher efficacy
Answer: B
*Rationale: Potency is measured by EC50 (lower EC50 = more potent). Efficacy
,(Emax) is the maximal effect, independent of potency. A more potent drug may
have lower efficacy (e.g., fentanyl vs. morphine in analgesia — both full agonists).*
5. A drug has an EC50 of 1 nM. Another drug that acts on the same receptor has
an EC50 of 100 nM. Which statement is correct?
• A) The first drug is more potent
• B) The second drug is more potent
• C) Both drugs have the same potency
• D) Potency cannot be compared
Answer: A
*Rationale: Lower EC50 = higher potency. The drug with EC50 1 nM is 100-fold
more potent than the drug with EC50 100 nM. Potency does not predict efficacy
(maximal response).*
6. A partial agonist differs from a full agonist in that a partial agonist:
• A) Has higher potency
• B) Has lower intrinsic activity (cannot produce maximal response)
• C) Binds irreversibly
• D) Only works on partial receptors
Answer: B
*Rationale: Partial agonists have intrinsic activity between 0 and 1 (e.g., 50% of
maximal response). They can act as antagonists in the presence of a full agonist
(competitive inhibition). Examples: buprenorphine (μ-opioid), aripiprazole (D2).*
7. Which of the following is an example of a partial agonist used clinically?
• A) Morphine (full μ-opioid agonist)
, • B) Buprenorphine (partial μ-opioid agonist)
• C) Naloxone (antagonist)
• D) Epinephrine (full β-adrenergic agonist)
Answer: B
Rationale: Buprenorphine is a partial μ-opioid agonist used for opioid use disorder
and pain. It has a ceiling effect for respiratory depression (safer than full agonists).
8. A patient takes a beta-blocker (antagonist) for hypertension. If the patient
receives a beta-agonist (e.g., isoproterenol), the expected response is:
• A) Increased heart rate
• B) Decreased heart rate
• C) No change in heart rate (blocked)
• D) Paradoxical tachycardia
Answer: C
Rationale: Competitive beta-blockers (propranolol, metoprolol) occupy beta-
receptors, preventing agonist binding and response. Higher doses of agonist can
overcome blockade (surmountable antagonism).
9. An irreversible antagonist differs from a reversible competitive antagonist
because:
• A) It binds covalently to the receptor
• B) Its effect can be overcome by increasing agonist concentration
• C) It has no effect on maximal response (Emax)
• D) It is always an inverse agonist
Answer: A
Rationale: Irreversible antagonists (e.g., phenoxybenzamine at α-receptors, aspirin
AND CORRECT ANSWERS (VERIFIED
ANSWERS) PLUS RATIONALES 2026
Section 1: Basic Principles of Pharmacodynamics
(Questions 1–25)
1. Which of the following best defines pharmacodynamics?
• A) The study of drug absorption, distribution, metabolism, and excretion
• B) The study of the biochemical and physiological effects of drugs and their
mechanisms of action
• C) The study of drug formulation and stability
• D) The study of adverse drug reactions
Answer: B
Rationale: Pharmacodynamics describes "what the drug does to the body" — the
interaction with receptors, signaling pathways, and resulting effects.
Pharmacokinetics (A) is "what the body does to the drug."
2. A drug that binds to a receptor and produces a maximal biological response is
called a:
• A) Partial agonist
• B) Antagonist
, • C) Full agonist
• D) Inverse agonist
Answer: C
*Rationale: A full agonist has high intrinsic activity (efficacy = 1) and produces a
maximal response (100% Emax) at sufficient concentration. A partial agonist (A)
produces a submaximal response even at full receptor occupancy.*
3. A drug that binds to the same receptor as an agonist but produces no response
and prevents the agonist from binding is a:
• A) Competitive antagonist
• B) Partial agonist
• C) Inverse agonist
• D) Allosteric modulator
Answer: A
Rationale: A competitive antagonist binds reversibly to the same site as the
agonist, blocking agonist binding without activating the receptor. It shifts the
dose-response curve to the right without changing Emax.
4. Which of the following statements about the dose-response curve is correct?
• A) The maximal effect (Emax) is determined by potency
• B) Potency is the dose required to produce 50% of maximal effect (EC50)
• C) Efficacy is the dose required to produce a response
• D) A more potent drug always has higher efficacy
Answer: B
*Rationale: Potency is measured by EC50 (lower EC50 = more potent). Efficacy
,(Emax) is the maximal effect, independent of potency. A more potent drug may
have lower efficacy (e.g., fentanyl vs. morphine in analgesia — both full agonists).*
5. A drug has an EC50 of 1 nM. Another drug that acts on the same receptor has
an EC50 of 100 nM. Which statement is correct?
• A) The first drug is more potent
• B) The second drug is more potent
• C) Both drugs have the same potency
• D) Potency cannot be compared
Answer: A
*Rationale: Lower EC50 = higher potency. The drug with EC50 1 nM is 100-fold
more potent than the drug with EC50 100 nM. Potency does not predict efficacy
(maximal response).*
6. A partial agonist differs from a full agonist in that a partial agonist:
• A) Has higher potency
• B) Has lower intrinsic activity (cannot produce maximal response)
• C) Binds irreversibly
• D) Only works on partial receptors
Answer: B
*Rationale: Partial agonists have intrinsic activity between 0 and 1 (e.g., 50% of
maximal response). They can act as antagonists in the presence of a full agonist
(competitive inhibition). Examples: buprenorphine (μ-opioid), aripiprazole (D2).*
7. Which of the following is an example of a partial agonist used clinically?
• A) Morphine (full μ-opioid agonist)
, • B) Buprenorphine (partial μ-opioid agonist)
• C) Naloxone (antagonist)
• D) Epinephrine (full β-adrenergic agonist)
Answer: B
Rationale: Buprenorphine is a partial μ-opioid agonist used for opioid use disorder
and pain. It has a ceiling effect for respiratory depression (safer than full agonists).
8. A patient takes a beta-blocker (antagonist) for hypertension. If the patient
receives a beta-agonist (e.g., isoproterenol), the expected response is:
• A) Increased heart rate
• B) Decreased heart rate
• C) No change in heart rate (blocked)
• D) Paradoxical tachycardia
Answer: C
Rationale: Competitive beta-blockers (propranolol, metoprolol) occupy beta-
receptors, preventing agonist binding and response. Higher doses of agonist can
overcome blockade (surmountable antagonism).
9. An irreversible antagonist differs from a reversible competitive antagonist
because:
• A) It binds covalently to the receptor
• B) Its effect can be overcome by increasing agonist concentration
• C) It has no effect on maximal response (Emax)
• D) It is always an inverse agonist
Answer: A
Rationale: Irreversible antagonists (e.g., phenoxybenzamine at α-receptors, aspirin
